DK1177190T3 - Anvendelse af selektive antagonister af alfa-1b-adrenerge receptor til behandling af sexuel dysfunktion - Google Patents

Anvendelse af selektive antagonister af alfa-1b-adrenerge receptor til behandling af sexuel dysfunktion

Info

Publication number
DK1177190T3
DK1177190T3 DK00927199T DK00927199T DK1177190T3 DK 1177190 T3 DK1177190 T3 DK 1177190T3 DK 00927199 T DK00927199 T DK 00927199T DK 00927199 T DK00927199 T DK 00927199T DK 1177190 T3 DK1177190 T3 DK 1177190T3
Authority
DK
Denmark
Prior art keywords
alpha
treatment
adrenergic receptor
sexual dysfunction
selective antagonists
Prior art date
Application number
DK00927199T
Other languages
English (en)
Inventor
Amedeo Leonardi
Gianni Motta
Rodolfo Testa
Giorgio Sironi
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Application granted granted Critical
Publication of DK1177190T3 publication Critical patent/DK1177190T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9433—(Nor)adrenaline
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Electrotherapy Devices (AREA)
DK00927199T 1999-05-07 2000-05-08 Anvendelse af selektive antagonister af alfa-1b-adrenerge receptor til behandling af sexuel dysfunktion DK1177190T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1999MI000995A IT1312310B1 (it) 1999-05-07 1999-05-07 Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale

Publications (1)

Publication Number Publication Date
DK1177190T3 true DK1177190T3 (da) 2006-02-20

Family

ID=11382912

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00927199T DK1177190T3 (da) 1999-05-07 2000-05-08 Anvendelse af selektive antagonister af alfa-1b-adrenerge receptor til behandling af sexuel dysfunktion

Country Status (25)

Country Link
US (2) US6303606B1 (da)
EP (1) EP1177190B1 (da)
JP (1) JP2002544158A (da)
KR (1) KR100696755B1 (da)
CN (1) CN1150187C (da)
AT (1) ATE308538T1 (da)
AU (1) AU765487B2 (da)
BR (1) BR0010348A (da)
CA (1) CA2366201A1 (da)
DE (1) DE60023686T2 (da)
DK (1) DK1177190T3 (da)
ES (1) ES2250130T3 (da)
HK (1) HK1039900B (da)
HU (1) HUP0201184A3 (da)
IL (1) IL146003A0 (da)
IT (1) IT1312310B1 (da)
MX (1) MXPA01011261A (da)
NO (1) NO321841B1 (da)
NZ (1) NZ515240A (da)
PL (1) PL196708B1 (da)
RU (1) RU2239633C2 (da)
SI (1) SI1177190T1 (da)
TW (1) TWI224503B (da)
WO (1) WO2000067735A2 (da)
ZA (1) ZA200110042B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
GB0000561D0 (en) * 2000-01-11 2000-03-01 Pfizer Ltd Treatment of diabetic ulcers
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
CA2538415A1 (en) * 2003-09-15 2005-03-24 Wilfred Wayne Lautt Use of antagonists of hepatic sympathetic nerve activity
US20050124625A1 (en) * 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
WO2005112889A2 (en) * 2004-05-20 2005-12-01 Recordati Ireland Limited Transmucosal delivery formulations
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
WO2006042701A1 (de) * 2004-10-18 2006-04-27 Polymun Scientific Immunbiologische Forschung Gmbh Liposomale zusammensetzung einen wirkstoff zur relaxierung glatter muskulatur enthaltend, die herstellung dieser zusammensetzung und deren therapeutische verwendung
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
JP2009513604A (ja) 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
KR20090042967A (ko) 2006-08-14 2009-05-04 베링거 인겔하임 인터내셔날 게엠베하 플리반세린 제형 및 이의 제조방법
AR062321A1 (es) 2006-08-25 2008-10-29 Boehringer Ingelheim Int Sistema de liberacion controlada y metodo para fabricarlo
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
CN101592613B (zh) * 2009-07-06 2011-12-21 广东省药品检验所 一种中成药、保健食品和食品中添加pde5型抑制剂的检测方法
JP5973994B2 (ja) 2010-09-13 2016-08-23 大塚製薬株式会社 複素環化合物
JP6415982B2 (ja) * 2012-03-12 2018-10-31 大塚製薬株式会社 複素環化合物
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
CA2880085C (en) 2012-06-04 2021-09-07 Diamedica Inc. Human tissue kallikrein 1 glycosylation isoforms
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
AU2017290593A1 (en) 2016-06-27 2019-01-03 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
WO2018165551A1 (en) 2017-03-09 2018-09-13 Diamedica Inc. Dosage forms of tissue kallikrein 1

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605897A (en) 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
US5474994A (en) 1992-05-26 1995-12-12 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A
IT1254469B (it) 1992-02-25 1995-09-25 Recordati Chem Pharm Derivati benzopiranici e benzotiopiranici
US5773457A (en) 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
DE69423533T2 (de) 1993-02-10 2000-08-24 B.M.R.A. Corp. B.V., Rotterdam Zubereitungen zur Behandlung von Impotenz, die ein Alpha-1 inhibitor und ein Alpha-2 inhibitor enthalten
US5565466A (en) 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
IT1270993B (it) * 1994-03-18 1997-05-26 Recordati Chem Pharm Derivati chinzolilamminici attivi come alfa-antagonisti
KR19980703052A (ko) 1995-03-14 1998-09-05 윌리엄 엘. 스미스 발기 기능장애의 예방 방법 및 키트
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
CA2232138A1 (en) 1995-09-29 1997-04-03 William C. Lumma Alpha 1b adrenergic receptor antagonists
US5700364A (en) 1995-10-30 1997-12-23 Merck & Co., Inc. Electrochemical oxidation
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
EP1027054A4 (en) * 1997-10-28 2002-11-04 Vivus Inc LOCAL CONTRIBUTION OF PHOSPHODIESTERASE INHIBITORS IN THE TREATMENT OF ERECTILE DYSFUNCTION
EP1027057A4 (en) 1997-10-28 2003-01-02 Vivus Inc TREATMENT OF FEMALE SEXUAL DISORDERS
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction

Also Published As

Publication number Publication date
CN1354749A (zh) 2002-06-19
HUP0201184A2 (en) 2002-10-28
HK1039900B (zh) 2006-02-03
TWI224503B (en) 2004-12-01
KR20020002494A (ko) 2002-01-09
NO321841B1 (no) 2006-07-10
PL351624A1 (en) 2003-05-19
US6953800B2 (en) 2005-10-11
ZA200110042B (en) 2002-07-02
SI1177190T1 (sl) 2006-02-28
KR100696755B1 (ko) 2007-03-19
NZ515240A (en) 2003-09-26
EP1177190A2 (en) 2002-02-06
ATE308538T1 (de) 2005-11-15
MXPA01011261A (es) 2002-08-12
AU4565400A (en) 2000-11-21
EP1177190B1 (en) 2005-11-02
CN1150187C (zh) 2004-05-19
CA2366201A1 (en) 2000-11-16
DE60023686T2 (de) 2006-07-20
NO20015428L (no) 2001-11-06
PL196708B1 (pl) 2008-01-31
WO2000067735A2 (en) 2000-11-16
WO2000067735A3 (en) 2001-02-01
US20020161009A1 (en) 2002-10-31
BR0010348A (pt) 2002-02-13
HK1039900A1 (en) 2002-05-17
ES2250130T3 (es) 2006-04-16
IL146003A0 (en) 2002-07-25
AU765487B2 (en) 2003-09-18
IT1312310B1 (it) 2002-04-15
NO20015428D0 (no) 2001-11-06
RU2239633C2 (ru) 2004-11-10
JP2002544158A (ja) 2002-12-24
US6303606B1 (en) 2001-10-16
DE60023686D1 (de) 2005-12-08
ITMI990995A1 (it) 2000-11-07
HUP0201184A3 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
DK1177190T3 (da) Anvendelse af selektive antagonister af alfa-1b-adrenerge receptor til behandling af sexuel dysfunktion
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
SV2002000195A (es) Compuestos farmaceuticamente activos ref. pcs10342 afae/bb
NO20032905L (no) Nye benzodiazepiner og beslektede heterocykliske derivater som er anvendelige som orexinreseptorantagonister
ATE303804T1 (de) Behandlung von sexueller funktionsstörung mit bombesin rezeptor antagonisten
DK1646389T3 (da) Pyrimidin-2,4-dionderivater som gonadotropinfrigörende hormonreceptorantagonister
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
AR002459A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
EA200201179A1 (ru) Производные 2-аминокарбонил-9h-пурина
DE60116353D1 (de) Hemmung der emetischen wirkung von metformin mit 5-ht3 rezeptor antagonisten
DK0626968T3 (da) Thiacykliske piperidinylderivater
EA200600188A1 (ru) Производные пиримидин-2,4-диона и их применение в качестве антагонистов рецепторов гонадолиберина
DK0975327T3 (da) Anvendelse af 5HT3-antagonister til befordring af tarmudskylning
HUP0100705A2 (hu) Hatóanyag-kombinációk alkalmazása, valamint ilyen kombinációkat tartalmazó gyógyszerkészítmények és készletek impotencia kezelésére
BR0007864A (pt) Composto, e, uso de um composto
EA200200207A1 (ru) Применение антагонистов cgrp и ингибиторов высвобождения cgrp для устранения приливов в период менопаузы
TR199902848T2 (xx) Ergolin t�revleri ve bunlar�n somatostatin resept�r antagonist olarak kullan�mlar�
DK1313485T3 (da) Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion
BG106602A (en) Formulation of substituted benzimidazoles
DK1109814T3 (da) 5-Heterocyclylpyrazolo[4,3-d]pyrimidin-7-oner til behandling af mandlig erektil dysfunktion
ES2091126T3 (es) Nuevos compuestos biciclicos de pirimidina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
EA200100618A1 (ru) Антагонист витронектинового рецептора
DK1497292T3 (da) Azaindolylpiperidinderivater som antihistamin- og antiallergimidler
DE60318716D1 (de) Thieno-pyrrole verbindungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren
PT1282617E (pt) Derivados de hidantoína com afinidade para os receptores da somatostatina